Shionogi & Co., Ltd.
FDA Approval for New COVID-19 Treatment | Shionogi & Co., Ltd. May 2026
Shionogi & Co., Ltd. obtained FDA approval in the United States for the anti-SARS-CoV-2 drug ensitrelvir on June 16, 2026. This achievement marks the first oral antiviral medication approved for post-exposure prophylaxis of COVID-19 globally, representing a significant advancement that accelerates the company's global expansion efforts.
Key Figures
- Approval Date: 2026-06-16
- Number of FDA Approvals Achieved: 1
- Reduction in COVID-19 development risk within 10 days of administration: 67%
AI要約
Overview of Financial Performance
Shionogi & Co., Ltd. announced that its US subsidiary received FDA approval on June 16, 2026, for the indication of post-exposure prophylaxis of COVID-19 with the anti-SARS-CoV-2 drug ensitrelvir. Based on positive results from the global Phase 3 post-exposure prevention trial (SCORPIO-PEP), this milestone signifies the world's first approval for an oral antiviral medication for post-exposure prophylaxis. The drug reduces the risk of developing COVID-19 by 67% up to 10 days after administration, with a favorable safety profile. Moving forward, the company aims to contribute to comprehensive infectious disease care as part of infection control measures and continues to expand globally.
Future Outlook and Corporate Activities
Shionogi & Co., Ltd. considers overcoming infectious disease threats a key management goal and is promoting R&D in infectious diseases. The FDA approval enables the company to expand sales in overseas markets such as the United States, while also pursuing license agreements to improve access for low- and middle-income countries. These developments are already incorporated into the consolidated earnings forecast for the fiscal year ending March 2027, and the company is expected to play an important role in infectious disease countermeasures moving forward.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
